Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)

Sheeba K. Thomas, MD, Jatin J. Shah, MD, Ashley N. Morphey, RN, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Krina K. Patel, MDMSc, Carla P Miller, RN, Suzanne Phillips, RN, Brandon N. Crumpton, Ralph J. Johnson, PhD, Lei Feng, MS, Swaminathan P Iyer, MD, Behrang Amini, MD PhD, Donna M. Weber, MD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2018-99-116464

Published: 2018

Journal Articles

Rash in Patients after T-Cell-Depleted Peripheral Blood Stem Cell Transplantation: Eosinophilia and Pruritus Do Not Distinguish Acute Graft-Versus-Host Disease from Drug Rash

Skylar A Klager, MS, Sean M Devlin, PhD, Margaret Hannum, MS, Ann A. Jakubowski, MD PhD, Alina Markova, MD

Blood (2018) 132 (Supplement 1): 4570.

https://doi.org/10.1182/blood-2018-99-110307

Published: 2018

Journal Articles

Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Sheeba K. Thomas, MD, Jatin J. Shah, MD, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Donna M. Weber, MD, Krina K. Patel, MDMSc, Lei Feng, MS, Behrang Amini, MD, Ashley Morphey, RN, Brandon Crumpton, Suzanne Phillips, RN, Carla Miller, RN, Mariann Gonzalez, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 840.

https://doi.org/10.1182/blood.V130.Suppl_1.840.840

Published: 2017

Journal Articles

Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report

Blood (2015) 126 (23): 3154.

https://doi.org/10.1182/blood.V126.23.3154.3154

Published: 2015

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Phase II Trial Of Brentuximab Vedotin For CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

Madeleine Duvic, MD, Michael Tetzlaff, MD, Audra L Clos, MD, Pamela Gangar, MD, Rakhshandra Talpur, MD

Blood (2013) 122 (21): 367.

https://doi.org/10.1182/blood.V122.21.367.367

Published: 2013

Journal Articles

Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

Madeleine Duvic, MD, Michael Tetzlaff, MD, Audra L Clos, MD, Pamela Gangar, MD, Rakhshandra Talpur, MD

Blood (2012) 120 (21): 3688.

https://doi.org/10.1182/blood.V120.21.3688.3688

Published: 2012

Journal Articles

Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care

Connie A. Sizemore, Pharm.D., Karen Manion, RN, Lawrence Morris, MD, Asad Bashey, MD, PhD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2010) 116 (21): 3525.

https://doi.org/10.1182/blood.V116.21.3525.3525

Published: 2010

Journal Articles

Recombinant Human Interleukin-7 (CYT107) Enhances CD4 and CD8 T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant In Patients with Myeloid Malignancies

Blood (2010) 116 (21): 674.

https://doi.org/10.1182/blood.V116.21.674.674

Published: 2010

Journal Articles

Results of a Phase I/II-Study on PCR-Based Pre-Emptive Therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem Cell Transplantation.

ZiYi Lim, Gordon Cook, Peter R. Johnson, Anne Parker, Mark Zuckerman, Ghulam J. Mufti, David Marks, Antonio Pagliuca

Blood (2007) 110 (11): 5011.

https://doi.org/10.1182/blood.V110.11.5011.5011

Published: 2007

Journal Articles

Daclizumab-Associated Erythroderma Is Associated with Rebound Increases in CD25-Positive CD4 Cells Following Treatment of Aplastic Anemia and Pure Red Cell Aplasia.

Steven J. Lemery, MD, Kenneth F. More, MD, Neal S. Young, MD, Elaine M. Sloand

Blood (2005) 106 (11): 1042.

https://doi.org/10.1182/blood.V106.11.1042.1042

Published: 2005

Journal Articles

High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL.

Rena Buckstein, M. Crump, Y. Shaked, D. Spaner, E. Piliotis, K. Imrie, R. Nayar, C. Foden, R. Turner, D. Taylor, S. Man, S. Baruchel, D. Stempak, I. Quirt, J. Sturgeon, F. Bertolini, R.S. Kerbel

Blood (2004) 104 (11): 4622.

https://doi.org/10.1182/blood.V104.11.4622.4622

Published: 2004

NARROW

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)

Rash in Patients after T-Cell-Depleted Peripheral Blood Stem Cell Transplantation: Eosinophilia and Pruritus Do Not Distinguish Acute Graft-Versus-Host Disease from Drug Rash

Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Phase II Trial Of Brentuximab Vedotin For CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care

Recombinant Human Interleukin-7 (CYT107) Enhances CD4 and CD8 T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant In Patients with Myeloid Malignancies

Results of a Phase I/II-Study on PCR-Based Pre-Emptive Therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem Cell Transplantation.

Daclizumab-Associated Erythroderma Is Associated with Rebound Increases in CD25-Positive CD4 Cells Following Treatment of Aplastic Anemia and Pure Red Cell Aplasia.

High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only